JP2023179752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023179752A5 JP2023179752A5 JP2023180474A JP2023180474A JP2023179752A5 JP 2023179752 A5 JP2023179752 A5 JP 2023179752A5 JP 2023180474 A JP2023180474 A JP 2023180474A JP 2023180474 A JP2023180474 A JP 2023180474A JP 2023179752 A5 JP2023179752 A5 JP 2023179752A5
- Authority
- JP
- Japan
- Prior art keywords
- gly
- linker
- peptide
- composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108010017447 4N1K peptide Proteins 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 102400000069 Activation peptide Human genes 0.000 claims 2
- 101800001401 Activation peptide Proteins 0.000 claims 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 claims 1
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 102100023704 Spermatogenic leucine zipper protein 1 Human genes 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169072 | 2016-05-10 | ||
| EP16169072.2 | 2016-05-10 | ||
| EP17154452.1 | 2017-02-02 | ||
| EP17154452 | 2017-02-02 | ||
| JP2018559205A JP7537074B2 (ja) | 2016-05-10 | 2017-05-10 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| PCT/EP2017/061151 WO2017194586A1 (en) | 2016-05-10 | 2017-05-10 | Agents that activate cd47 and their use in the treatment of inflammation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559205A Division JP7537074B2 (ja) | 2016-05-10 | 2017-05-10 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023179752A JP2023179752A (ja) | 2023-12-19 |
| JP2023179752A5 true JP2023179752A5 (enExample) | 2024-04-08 |
Family
ID=58772857
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559205A Active JP7537074B2 (ja) | 2016-05-10 | 2017-05-10 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2022035726A Pending JP2022078244A (ja) | 2016-05-10 | 2022-03-08 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2023180474A Pending JP2023179752A (ja) | 2016-05-10 | 2023-10-19 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559205A Active JP7537074B2 (ja) | 2016-05-10 | 2017-05-10 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2022035726A Pending JP2022078244A (ja) | 2016-05-10 | 2022-03-08 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11142548B2 (enExample) |
| EP (1) | EP3454884B1 (enExample) |
| JP (3) | JP7537074B2 (enExample) |
| CA (1) | CA3023802C (enExample) |
| WO (1) | WO2017194586A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3023802C (en) * | 2016-05-10 | 2025-02-04 | Inserm (Institut De La Sante Et De La Recherche Medicale) | ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION |
| US20210052543A1 (en) | 2018-01-09 | 2021-02-25 | Brigham Young University | Compositions and Methods for Treating Pain with Wogonin |
| WO2022113887A1 (ja) * | 2020-11-27 | 2022-06-02 | 京都府公立大学法人 | 炎症性網膜疾患の判定方法、炎症性網膜疾患治療剤、及び炎症性網膜疾患治療剤のスクリーニング方法 |
| WO2022232001A1 (en) * | 2021-04-26 | 2022-11-03 | President And Fellows Of Harvard College | Cd47 compositions and methods for the treatment of degenerative ocular diseases |
| CN116831988A (zh) * | 2023-06-13 | 2023-10-03 | 南京鼓楼医院 | 一种载肽模拟物pkhb1的脂质体眼用制剂及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| US6001962A (en) | 1996-11-15 | 1999-12-14 | The Regents Of The University Of California | Modified Fas ligands |
| CA2226962A1 (en) * | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| US6846637B1 (en) | 1998-06-18 | 2005-01-25 | Imed Ab | Fas peptides and antibodies for modulating apoptosis |
| EP2479284B1 (en) | 2006-07-13 | 2017-09-20 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
| CA2747678A1 (en) * | 2008-12-19 | 2010-06-24 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| JP2012531893A (ja) | 2009-06-29 | 2012-12-13 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | アルギナーゼ製剤および方法 |
| WO2011137363A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| ES2616010T3 (es) | 2010-05-14 | 2017-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Anticuerpos monoclonales humanizados y quiméricos a CD47 |
| US20140127269A1 (en) * | 2012-02-13 | 2014-05-08 | The Schepens Eye Research Institute, Inc. | Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof |
| JP2015520178A (ja) * | 2012-06-06 | 2015-07-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 癌の処置における使用のための方法及び医薬的組成物 |
| US10004780B2 (en) | 2012-10-17 | 2018-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD) |
| EP3581653A3 (en) | 2013-12-23 | 2020-02-19 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for treating cancer using peptide nucleic acid-based agents |
| EP2898896A1 (en) * | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| ES2875057T3 (es) | 2014-09-17 | 2021-11-08 | Us Health | Anticuerpos anti-CD276 (B7H3) |
| KR20230004907A (ko) | 2014-10-14 | 2023-01-06 | 립타이드 바이오사이언스, 인코포레이티드 | 항-염증 특성을 갖는 펩타이드 |
| FR3036620B1 (fr) * | 2015-05-27 | 2017-09-01 | Inst Biophytis | Utilisation de 3-desoxyanthocyanidines pour le traitement de maladies oculaires |
| CA3023802C (en) * | 2016-05-10 | 2025-02-04 | Inserm (Institut De La Sante Et De La Recherche Medicale) | ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION |
-
2017
- 2017-05-10 CA CA3023802A patent/CA3023802C/en active Active
- 2017-05-10 US US16/300,438 patent/US11142548B2/en active Active
- 2017-05-10 JP JP2018559205A patent/JP7537074B2/ja active Active
- 2017-05-10 WO PCT/EP2017/061151 patent/WO2017194586A1/en not_active Ceased
- 2017-05-10 EP EP17725893.6A patent/EP3454884B1/en active Active
-
2022
- 2022-03-08 JP JP2022035726A patent/JP2022078244A/ja active Pending
-
2023
- 2023-10-19 JP JP2023180474A patent/JP2023179752A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023179752A5 (enExample) | ||
| JP2025063029A5 (enExample) | ||
| JP2018171063A5 (enExample) | ||
| Zhao et al. | Biochemical mechanism of HIV-1 Vpr function. Oligomerization mediated by the N-terminal domain. | |
| JP2019122392A5 (enExample) | ||
| Vitali | Proline-rich peptides: Multifunctional bioactive molecules as new potential therapeutic drugs | |
| JP2018515085A5 (enExample) | ||
| JP2012520059A5 (enExample) | ||
| CA2412278A1 (en) | Polymer-modified synthetic proteins | |
| JP2018536405A5 (enExample) | ||
| JP2023029902A5 (enExample) | ||
| JP2018538356A5 (enExample) | ||
| JP2020517260A5 (enExample) | ||
| AU2002365196B8 (en) | Multimeric proteins and methods of making and using same | |
| AU2009312892A1 (en) | Neuropeptide-2-receptor (Y-2r) agonists and uses thereof | |
| JP2022126804A5 (enExample) | ||
| CN104159913A (zh) | 针对细胞内靶分子的结合剂 | |
| JP2014517690A5 (enExample) | ||
| JP6893163B2 (ja) | 経口投与 | |
| EP1756160B1 (en) | Oligomeric peptides and their use for the treatment of hiv infections | |
| JP2017036294A (ja) | 非ペプチドヒンジ部含有フレキシブル抗体様分子 | |
| JP2019521963A5 (enExample) | ||
| CN110461861A (zh) | 人参肽和人参肽类似肽的制备和利用 | |
| CN103755810B (zh) | 一种长效hiv‐1膜融合抑制剂 | |
| JP2020127419A5 (enExample) |